Raymond James raised the firm’s price target on Dyne Therapeutics to $56 from $27 and keeps a Strong Buy rating on the shares after Dyne Therapeutics announced initial clinical data from its ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 and its DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping. DYNE-101 is “clearly active” and DYNE-251 also looks active, says the analyst, who argues that today’s data “provides clear and convincing validation” of Dyne’s platform.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DYN:
- Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE™ Platform in Developing Therapeutics for Rare Muscle Diseases
- Dyne Therapeutics to Host Virtual Event Tomorrow, January 3 at 8:00 AM ET, to Present Initial Clinical Data from ACHIEVE and DELIVER Trials
- Oppenheimer, Wedbush say buy these biotech stocks for 2024
- JPMorgan healthcare/biotech analysts hold analyst/industry conference call
- Dyne Therapeutics to Present at November Investor Conferences